Over the past decade, large multicenter trials have unequivocally demonstrated that decreasing low-density lipoprotein (LDL) cholesterol can reduce both primary and secondary cardiovascular events in patients at risk. However, even in the context of maximal LDL lowering, there remains considerable residual cardiovascular risk. Some of this risk can be attributed to variability in high-density lipoprotein (HDL) cholesterol. As such, there is tremendous interest in defining determinants of HDL homeostasis. Risk prediction models are being constructed based upon (1) clinical contributors, (2) known molecular determinants and (3) the genetic architecture underlying HDL cholesterol levels. To date, however, no single resource has combined these factors within the context of a practice-based data set. Recently, a number of academic medical centers have begun constructing DNA biobanks linked to secure encrypted versions of their respective electronic medical record. As these biobanks combine resources, the clinical community is in a position to characterize lipid-related treatment outcome on an unprecedented scale.
Introduction
Lipoprotein homeostasis is a complex process. 1, 2 Free fatty acids (FFA) and triglycerides (TG) absorbed from within the gastrointestinal lumen are shuttled to the liver in chylomicrons. FFA and TG are then combined with apolipoproteins, phospholipids, free cholesterol and cholesterol esters (CEs), to form low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL). These particles are interconverted by lipoprotein lipase (LPL), and variability in LPL activity is associated with derangements in lipid homeostasis. 3 Although VLDL and LDL are atherogenic, association between these large lipoproteins and cardiovascular disease (CVD) is modified by a number of additional lipid-dependent and lipid-independent risk factors. 4 Thus, all lipoproteins are not uniformly atherogenic. High-density lipoprotein (HDL) particles have direct antiatherogenic properties in transgenic mouse models. 5 Although HDL particles may serve as a source of CEs for the more atherogenic LDL and VLDL, the HDL particles themselves Conversely, scavenger receptor class B-1 (SRB1) moves CE forward into the liver and steroidogenic tissues (adrenals, ovaries, testes). Like CETP, the net effect is reduction of CE within the HDL particles. SRB1 multimers form within the plasma membranes of target cells (for example, hepatocytes), possibly requiring the presence of HDL particles to facilitate their assembly. 9 Each SRB1 monomer has two membrane spanning regions. Although the extracellular loop of SRB1 has moderate affinity for many apolipoproteins (that is, functioning as a scavenger protein), SRB1 can only mobilize CE in the presence of ApoA-1. SRB1 is also capable of extracting phospholipids and TG. Thus, SRB1 generates HDL particles which also migrate in the a-position on nondenaturing electrophoretic profiles. 8 
Intravascular remodeling
HDL particles undergo considerable remodeling within the vascular space. Nascent HDL particles contain two copies of ApoA-I and very little lipid (less than 10%). 8 These particles acquire free and esterified cholesterol within the vascular lumen, through mechanisms introduced above. ApoA-I is present on most HDL particles, representing approximately 70% of the protein content of the total circulating pool of HDL. 8 Apo A-II is the second most abundant HDL protein. Other HDL proteins include inflammatory markers (for example, serum amyloid A). 8 Further intravascular remodeling is facilitated by lipolytic enzymes, which transfer additional surface components (for example, other apolipoproteins such Apo-E) and additional core components (for example, TGs) to the maturing HDL particle. At least three lipolytic enzymes modify HDL composition. 1, 8 They are endothelial lipase (LIPG), hepatic lipase (LIPC), and LPL.
LPL is synthesized by adipose tissue and skeletal muscle. Its enzymatic activity favors the lipolysis of TGs (that is, phospholipase activity is minor). LIPC is synthesized by heptocytes, and it has both phospholipase and TG lipase activity. Further, LIPC has greater activity against HDL than VLDL or chylomicrons. LIPC thus converts larger HDL particles into smaller HDL remnants. 10 As discussed later, this process is accelerated during insulin resistance and hypertriglyceridemia. 11, 12 Conversely, LIPG is primarily a phospholipase, with relatively little TG-lipase activity. In general, LIPG hydrolyzes the phospholipids of HDL, whereas LIPC hydrolyzes the TG of HDL. Other phospholipases (for example, soluble PLA2) are capable of hydrolyzing HDL phospholipids during inflammatory states. The observation that LIPG is upregulated by cytokines may provide a link between inflammation and low HDL levels.
Reverse cholesterol transport
As noted, circulating levels of HDL cholesterol are determined by the dynamic equilibrium of three processes: (1) lipoprotein biosynthesis, (2) particle remodeling in the vascular space and (3) particle disassembly. At present, there is tremendous interest in pharmacological optimization of these processes, particularly with a goal toward leveraging HDL to shuttle cholesterol out of atherosclerotic plaques and back to the liver for hepatobiliary elimination (reverse cholesterol transport). 13 The ATP-binding cassette transporter protein, ABCA1, may be able to export free cholesterol from macrophages in lipid plaques, by combining free cholesterol with nascent HDL and lipid-poor apolipoproteins.
14 Free cholesterol can also be moved out of macrophages through alternate membrane transporters (for example, ABCG1), but these latter transporters appear to move macrophage cholesterol preferentially into mature cholesterol-laden HDL particles. 14, 15 After further remodeling of the HDL particle pool by enzymes such as CETP and LIPG, and driven by mass action, HDL particles can shuttle cholesterol back into hepatocytes via SRB1.
Clinical variables influencing this dynamic equilibrium are reviewed below, followed by a discussion of ongoing efforts to quantify treatment efficacy within the world's growing population-based biobanks. This unique integration of clinical data facilitates the construction of improved risk prediction models.
Clinical contributors to HDL level
Lipoprotein homeostasis is strongly influenced by changes in body weight, body composition and physical activity. 11, [16] [17] [18] [19] The current obesity epidemic represents a major international health crisis, 20 and the increased cardiovascular mortality associated with weight gain is observed in all races. 21 The metabolic complications of weight gain are often more life-threatening than obesity itself. For instance, obese individuals tend to have lower circulating levels of HDL cholesterol 22 and each 1 mg per 100 ml reduction in HDL cholesterol level is associated with a 6% increase cardiovascular risk. 23 Furthermore, obesity (that is, increased visceral fat mass) is associated with a reduction in mean HDL particle size, yielding a shift on density gradient ultracentrifugation toward a decreasing concentration of the larger HDL 2 subclass, and an increasing concentration of the smaller HDL 3 subclass. 24 In obese study subjects, low-HDL dyslipidemia is further characterized by HDL 3 particles that are deficient in otherwise normal antiatherogenic properties. 25 Thus, the shift to HDL 3 as well as the development of HDL 3 particle dysfunction contributes to net cardiovascular risk. 26 Atherogenic dyslipidemia is also defined by a constellation of lipoprotein abnormalities that include high serum TG levels and a shift toward smaller more dense LDL particles. 19, 27, 28 LDL particles typically migrate in the b-position on non-denaturing electrophoretic profiles and (as noted above) mature HDL particles migrate in the a-position. The distribution of each (and therefore the mean particle size) is highly intercorrelated with TG concentration. 28 Although elevated TG levels and alteration in HDL cholesterol can occur in the absence of other metabolic abnormalities, both phenotypes often accompany insulin resistance. 17, 24, 29 This association appears to be driven by two mechanisms. Insulin resistance directly impacts HDL particle composition by altering the expression and activity of LIPC. 12 As introduced above, LIPC converts larger HDL particles into smaller HDL remnants, 10 and this process is clearly accelerated during insulin resistance 12 The resulting remnant HDL particles have altered fluidity, as well as changes in ApoA-I conformation and higher concentrations of FFA. In this context, the HDL particles generated by LIPC activity appear to be cleared faster (that is, insulin resistance increases HDL catabolism). HDL catabolism is further altered in insulin-resistant subjects who develop hypertriglyceridemia. 8 CETP-mediated heterotransfer of lipids (that is, depletion of CE and enrichment of TG) is increased during hypertriglyceridemia, further altering the stability of HDL.
In fact, hypertriglyceridemia is the most common lipid abnormality observed within clinical syndromes of insulin resistance, and this abnormality is due in part to increased hepatic production of VLDL. 8 Due to competition for saturable removal processes, 30 elevated TG levels become particularly evident during the postprandial period. 31 In the fasting state, a net increase in TG/HDL ratio is observed by some investigators to be more predictive of insulin resistance than the presence of abdominal obesity. 32 The prevalence of this phenomenon is rapidly rising.
Biological candidate genes
The physiologic insulin-mediated stimulation of LPL activity within skeletal muscle and adipose tissue is also altered in obese subjects with insulin resistance. 33, 34 Rare subjects with heritable LPL deficiency are known to have low circulating levels of HDL cholesterol. 35 Other monogenic forms of low HDL dyslipidemia have also been reported (for example, Tangier disease, due to variants in ABCA1, ApoA-I or cholesterol acyltransferase). 2, 36 Recently, one of the most interesting treatment targets for obesity-related dyslipidemia has been the endocannabinoid (eCB) system. 37 The eCB system consists of two cannabinoid receptors, CB1 and CB2, 38 and emerging data support the fundamental hypothesis that dyslipidemia is partly influenced by overactive signaling at the level of CB1. 37 This claim is supported by multiple recent reports. In Europe, randomized placebo-controlled clinical trials have demonstrated that use of a CB1 receptor antagonist (rimonabant, 20 mg daily) is associated with a greater mean weight reduction than placebo after 1 year of therapy (À6.6±7.2 kg versus À1.8±6.4 kg; Po0.001). 39 This finding was subsequently validated in a similar study involving North American study subjects, wherein rimonabant (20 mg daily) was also associated with a greater mean weight reduction than placebo after 1 year of therapy (À6.3 ± 0.2 kg versus À1.6 ± 0.2 kg; Po0.001). 40 Both trials revealed a greater improvement in metabolic parameters (including HDL cholesterol) than that expected based upon weight loss alone. 41 In an analysis of covariance (correcting for weight loss from baseline through standard regression methods), investigators found that patients taking rimonabant developed an increase in HDL levels, and a decrease in TG levels, more than twice that anticipated based upon weight loss alone. 39, 40, 41 As an acquired (drug-induced) change in eCB/CB1 signaling clearly modifies HDL and TG levels, it is likely that genetic variability in eCB/CB1 signaling contributes to the development of dyslipidemia. 42 We recently tested this claim in one of the most rigorously phenotyped familybased obesity study cohorts in the United States.
43 CNR1 gene variability was associated with high TG and low HDL levels. Studies in the original cohort provide insight into the mechanism; the biological link between genetic variability in eCB/CB1 signaling and dyslipidemia appears to be independent of insulin responsiveness (based upon phenotypes derived from a frequently sampled intravenous glucose tolerance test: S i , S g , AIR g and D I ). 44 Whether the eCB/CB1 signaling variants identified in this cohort will be causative in other populations of unrelated individuals remains unclear. 45, 46 Positional candidate genes Characterization of the genetic architecture underlying clinical derangements in lipid homeostasis has not been limited to biological candidate genes; early on, some progress was made in the identification of positional candidate genes as well. Before 2004, linkage studies (in families) reported associations between various loci and lipoprotein levels as quantitative traits. Many of these associations were never replicated. More recently, resources have been reallocated toward whole genome scanning, with dense scanning platforms in large cohorts of unrelated individuals. Although these efforts appear to be providing some insight into signaling pathways previously unrecognized as impacting lipid homeostasis, most associations represent the reidentification of previously characterized biological candidate genes.
For instance, in a recent multicenter genome scanning effort involving more than 8000 study subjects from three combined cohorts, six previously recognized loci (containing twelve biological candidate genes) were validated with respect to their association with HDL cholesterol. 47 Each of these six loci contained at least one of the biological candidate genes discussed above (for example, ABCA1, APOA1, CETP, LIPC, LIPG and LPL). In addition to these six previously recognized loci, the investigators also identified a novel gene associated with HDL, GALNT2 (encoding an enzyme involved in the post-translational glycosylation of proteins). 47 Each copy of the minor allele for GALNT2 was associated with a 1.6 mg per 100 ml decrease in HDL. Further, GALNT2 was also idenitifed as one of five new loci associated with TG levels in the same study population. 47 These results have clearly been replicated. Willer and colleagues identified nine loci that were associated with HDL in a large multicenter study of similar design. 48 Many of the lipolytic enzymes and transporters outlined above were also contained within the nine loci identified by the latter group (for example, ABCA1, LPL, LIPG, CETP, cholesterol acyltransferase and GALNT2). However, as these loci collectively explain o5% of the HDL trait variance in these populations, much remains to be learned about the basic biology of dyslipidemia.
Large consortia are therefore being constructed to facilitate the identification of additional loci through metaanalyses leveraging genome wide data in populations and treatment trials. 49 To date, nearly 100 variants influencing lipid homeostasis have been reported. A small subset of these loci appear to be independently associated with CVD. 50 
Therapeutic interventions
Statins The large majority of cholesterol within cells is derived through de novo synthesis. Free cholesterol is built from simple 2-carbon fragments through a relatively linear biosynthetic pathway, 51 and the rate limiting enzyme in cholesterol biosynthesis is HMG-CoA reductase. Large, multicenter trials have demonstrated that attenuation of endogenous cholesterol biosynthesis through the use of HMG-CoA reductase inhibitors (statins) can reduce the likelihood of both primary and secondary cardiovascular events in patients at risk. [52] [53] [54] [55] [56] At present, there are six commercially available drugs within this class: lovastatin (approved by the FDA (Food and Drug Administration) in 1987), simvastatin (1988), pravastatin (1991), fluvastatin (1994), atorvastatin (1997) and rosuvastatin (2003) . 57 Each of these drugs is highly efficacious (representing 30-50% risk reduction depending upon dose and upon clinical context).
Although statins are known to interact with a variety of cellular processes, each drug in this class appears to derive its primary therapeutic effect by attenuating endogenous lipoprotein synthesis and upregulating the expression of membrane bound LDL cholesterol receptors. 58 Although these agents markedly reduce circulating levels of LDL cholesterol, their effect on HDL has been modest 59 : HDL levels increase 5-10% on statins. 60, 61 Further, the shape of the dose-response relationship between statins and HDL cholesterol varies from drug to drug. 61 Although simvastatin appears to raise HDL consistently at all common doses, the response to atorvastatin may be biphasic (diminished at higher doses). 61 This observation may reflect a differential effect of inhibiting cholesterol biosynthesis on the remodeling of lipoproteins.
Ezetimibe
Under normal physiologic conditions, 20% of cholesterol stores are derived from dietary sources (that is, exogenous uptake). Within the gastrointestinal tract, cholesterol uptake is facilitated by Niemann-Pick C1 like 1, a protein found in the brush border membrane of enterocytes. 62 Ezetimibe lowers cholesterol levels through inhibition of cholesterol uptake in the small intestine, at the level of Niemann-Pick C1 like 1. 63 Ezetimibe has been used clinically since 2002.
Following absorption, more than 90% of this drug undergoes enterohepatic circulation (that is, passes through the portal circulation to the liver, then the majority of the drug reenters the small intestine via the bile, where it blocks further cholesterol uptake). 63 In the liver, ezetimibe undergoes glucuronidation. Primary phase II enzymes are UGT1A1, UGT1A3 and UGT2B15, 64 and the resulting bioactive glucuronidated derivatives keep cycling and reblocking cholesterol uptake. 65, 66 Thus, ezetimibe monotherapy can reduce LDL levels by 20%. [67] [68] [69] [70] [71] [72] When combined with a statin, LDL reduction is typically 25-50%. 72, 73 The effect of ezetimibe on HDL is relatively small, and its overall clinical benefit remains controversial. 74 As discussed in a later section of this review, the ARBITER (arterial biology for the investigation of the treatment effects of reducing cholesterol) trials have been constructed to clarify this controversy. 75 Torcetrapib Both classes of drugs discussed above modify the availability of free cholesterol. As noted, however, lipoproteins contain esterified cholesterol in large amounts. As CETP facilitates the movement of CEs from HDL to the more atherogenic LDL, there has recently been tremendous interest in the potential for CETP inhibitors to reduce vascular disease. 7, 14, 76, 77 As some studies indicate that CETP deficiency may be cardio-protective, other studies suggest increased cardiovascular risk. 78, 79 Clinical studies conducted with CETP inhibitors have yielded equally conflicting results. In a recent trial evaluating 15 000 patients at risk, randomized to either LDL reduction with atorvastatin alone, or LDL reduction with atorvastatin plus HDL increase with torcetrapib, subjects on combination therapy (atorvastatin plus torcetrapib) were observed to have a higher frequency of angina, revascularization, myocardial infarction, heart failure and death. 7 This finding was not anticipated. There is growing evidence suggesting that this discrepancy (that is, between improved lipid panels and higher frequency of adverse cardiovascular events on torcetrapib) may have been due to altered distribution of HDL particle subtypes, toward a more pro-inflammatory atherogenic form of HDL. Newer CETP inhibitors appear to increase HDL and decrease TG levels (without altering blood pressure). 80 Through proteomics, investigators are now gaining deeper insight into the molecular heterogeneity of HDL particles. 81, 82 In a comparison between HDL particles obtained from control patients and patients with coronary artery disease, lipoproteins from patients with greater disease burden had higher levels of many acute-phase response proteins, as well as a differential distribution of apoplipoproteins. 81, 83 Thus, in addition to HDL cholesterol concentration, HDL particle composition is an important determinant of risk.
Fibric acid derivatives
The relationship between HDL cholesterol concentration and HDL particle size is strongly dependent upon TG homeostasis. As noted, fasting TG levels are an independent predictor of HDL particle size. 24 Fibric acid derivatives lower TG levels by activating peroxisome-proliferator-activated receptors (PPAR). 84 There are several molecular PPAR subtypes (a,b/d and g) which can be activated by endogenous lipids (fatty acids, eicosanoids and oxidized phospholipids). 85 Two exogenous ligands are commonly used to modulate lipid homeostasis through PPARa. In vitro, fenofibrate acts as a full agonist at PPARa, whereas gemfibrozil appears to be a partial agonist. 85 PPAR-a activation promotes the catabolism of fatty acids through b-oxidation. 85 When bound by ligand, PPAR-a heterodimerizes with the retinoic acid receptor (RÂR) and binds to PPAR response elements 85, 86 in genes important to lipid metabolism and glucose homeostasis. 87 When activated, PPAR-a induces acyl-coenzyme A synthetase, a key enzyme in the esterification of fatty acids (preventing the cellular efflux of fatty acids), as well as carnitine palmitoyltransferase type 1, an enzyme involved in the mitochondrial fatty acid oxidation in highly active tissues (for example, cardiac and skeletal muscle). [84] [85] [86] [87] PPAR-a activation thus limits the amount of FFA available for hepatic synthesis of TG-rich lipoproteins like VLDL. The net effect is a reduction in TG.
Fenofibrate and gemfibrozil directly impact HDL composition, through PPAR-a-mediated induction of hepatic lipase (LIPC). 85 As noted earlier, LIPC converts larger HDL particles into smaller HDL remnants. 10 PPAR-a also regulates HDL homeostasis by modulating expression of Apo-I, Apo-II, ABCA1 and SRB1. 85, 86 Ligand-activated PPAR-retinoid X receptor heterodimers facilitate the transrepression of anti-inflammatory gene products within the vascular endothelium, vascular smooth muscle and within cells of the immune system (for example, CRP, COX-2). 87 It is therefore likely that fibric acids influence the HDL proteome in a manner not yet fully characterized.
Fibrates are particularly effective in improving lipid parameters in patients with dyslipidemia due to type II diabetes mellitus. 88 Fenofibrate reduces TG levels nearly 50% in such patients. 89, 90 Modest improvements in LDL and HDL are observed as well. In the FIELD (fenofibrate intervention and event lowering in diabetes) trial (nearly 10 000 diabetic subjects with and without known coronary artery disease), the use of fenofibrate was associated with a reduction in myocardial infarction (hazard ratio 0.76, 95% confidence interval 0.62-0.94; P ¼ 0.01), as well as a reduction in the frequency of coronary artery revascularization (hazard ratio 0.79, 95% confidence interval 0.68-0.93; P ¼ 0.003). 88 Conversely, gemfibrozil appears to lower TG levels by approximately 35%. 91 In the Helsinki Heart Study, gemfibrozil was efficacious in reducing coronary events in 4000 men at moderate risk of coronary artery disease followed longitudinally (34% risk reduction after 5 years, Po0.05). 91 On average, LDL levels were decreased by 11% and HDL levels were increased by 11%. In subanalyses using overweight patients with fasting TGs 4200 mg per 100 ml (and HDL levels o40 mg per 100 ml), gemfibrozil reduced coronary risk by 78% (Po0.002). 92 Gemfibrozil was also associated with a 22% reduction in adverse coronary events in patients with known coronary artery disease followed longitudinally in the VA-HIT (veterans affairs high-density lipoprotein intervention) trial. 93, 94 Nearly 25% of all patients enrolled in the VA-HIT trial had type II diabetes mellitus.
Niacin
Niacin is efficacious at optimizing TG levels and HDL levels. 95 Niacin improves these lipid parameters through two mechanisms: (1) it increases sequestration of TGs in adipose (resulting in a reduction in the release of FFAs), and (2) it decreases synthesis of TGs in the liver (attenuating hepatic production of VLDL). In hepatocytes, esterification of diacylglycerols to TG is catalyzed by diacylglycerol acyl transferase-2. Niacin has been shown to non-competitively inhibit diacylglycerol acyl transferase-2, decreasing TG production. 96 In adipose, activation of a G-protein-coupled receptor called HM74A (GPR109A) results in the inhibition of hormone sensitive lipase through a mechanism dependent upon cyclic adenosine monophosphate. [97] [98] [99] The net effect is attenuation of the conversion of TG into FFA, keeping TG sequestered in the adipose. Although niacin is not a physiological ligand for HM74A, it can activate the receptor at high concentrations. 97, 98 As the effect of niacin is concentration-dependent, lipase activity can be inhibited almost 100%. 99 Niacin also increases HDL levels, by blocking the catabolism of these particles. Plasma turnover studies in humans 95, 96 Thus, raising HDL through the use of niacin may represent a valid clinical strategy for the reduction of cardiovascular risk. Data reported by the ARBITER 2 trial have indicated that niacin provides added benefit when given in addition to statin monotherapy in the stabilization of atherosclerotic carotid artery disease. 100 At this point, it remains unclear whether the added benefit attributed to niacin was due to additional LDL lowering, versus optimization of HDL and/or lipoprotein particle composition. To address this question within the context of carotid disease, the ARBITER 6-HALTS (6-HDL and LDL treatment strategies in atherosclerosis) trial will determine if combined optimization of LDL and HDL (statins plus niacin) is clinically superior to more aggressive LDL lowering (statin plus ezetimibe). 75 As noted earlier, a 1 mg per 100 ml increase in HDL cholesterol can decrease the risk for CVD as much as 6%. 23 There is also additional clinical benefit to be gained by lowering TG level (even when LDL cholesterol has already been substantially reduced). As shown in a post hoc evaluation of the PROVE IT-TIMI 22 trial, 101 on-treatment plasma TG levels o150 mg per 100 ml were independently associated with reduced risk of recurrent coronary events. In fact, after adjusting for non-HDL cholesterol and other clinical covariates, each 10 mg per 100 ml decrease in TG level is associated with an additional 1.4% reduction in the overall risk of developing CVD.
Modeling outcome
Treatment trials such as those introduced above will continue to inform our ongoing efforts to direct pharmacological intervention based on individualized risk (that is, the presence or absence of modifiable cardiac risk factors). There is also growing interest in the characterization of genetic risk determinants. The application of such determinants will be challenging, because the genetic architecture underlying cardiac risk factors such as low HDL dyslipidemia may be quite different from the genetic architecture underlying adverse cardiovascular events. 50 Further, data indicate that the clinical response to pharmacological intervention (for example, drug-induced change in lipid levels) is attributable to yet another set of genetic predictors. 49, 102 The identification of genetic determinants of treatment response has, however, been somewhat limited. Although markers for change in LDL cholesterol are now being reported, the genetic predictors of change in HDL cholesterol remain largely unsurveyed.
Modeling treatment-induced changes for HDL cholesterol will require large population-based cohorts. As discussed, drug-induced changes in HDL cholesterol are somewhat smaller in magnitude than drug-induced changes in LDL cholesterol, and the clinical variables influencing HDL cholesterol are many. To facilitate the construction of accurate prediction models for cardiometabolic risk, the eMERGE network (electronic medical records and genomics) has begun extracting lipid data from several of the world's growing biobank cohorts (www.gwas.net). We have begun modeling these variables in the Marshfield Clinic Personalized Medicine Research Project (PMRP), a dynamic community-based biobank located in the mid-western United States. 103 This population has a distribution of fasting lipid levels similar to that reported by NHANES III. 104 At present, the Marshfield biobank contains data from nearly 20 000 adult participants; more than 10 000 individuals (54%) have impaired fasting glucose (IFG); 48000 (41%) have hypertriglyceridemia; 49000 (48%) have reduced levels of HDL cholesterol according to criteria published by National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III). 6, 105 Using this cohort of 20 000 adults (age range 18-98 years, median 46 years), we previously extracted all lipid data, censored HDL data according to relevant comorbidities, and applied population trends to adjust age and body mass index for individual differences in the availability of HDL over time. A repeated measures model was published for males and females. 103 To illustrate the relative contribution of body composition, representative data are shown below for HDL as a function of body mass index in this cohort.
If individualized pharmacologic intervention is to become a common clinical reality, risk assessment must be based upon the interaction(s) of metabolic risk determinants such as these within a variety of subpopulations. A recent comparative effectiveness review commissioned by the Agency for Healthcare Research and Quality (AHRQ) specifically addressed this need by evaluating outcome in subjects with (and without) various dyslipidemias. The findings suggest that treatment modality should be directed by comorbidity. (Figures 1 and 2 ) Although the evidence supporting combination therapy (that is, multiple lipidmodifying agents) versus high-dose statin therapy remains insufficient to guide clinical decisions in the general population (AHRQ publication no: 09-EHC024-EF, 2009), patients with metabolic comorbidities-such as those subjects with elevated body mass index in the right half of Figure 1 -are likely to benefit from combination therapy targeted toward all lipid components. Thus, biobanks in the eMERGE network (www.gwas.net) may have the capability to more accurately characterize the impact of pharmacologic intervention on outcome, for all possible permutations of common cardiometabolic risk determinants.
We have also previously shown that lipid data can be efficiently extracted and annotated at first exposure to a relevant lipid-altering medication using electronic health records linked to secure encrypted databases. This is illustrated below for 20 randomly sampled male subjects from eMERGE.
This approach can be used to describe variation in drug response in large populations. For example, we have also previously linked accurate drug exposure histories (including start date, stop date and dose) with clinical lipid data to construct full dose-response relationships for HMG-CoA reductase inhibitors (statins). 106, 107 An example is shown in Figure 3 , for HDL and TG, using a test set of 100 participants exposed to atorvastatin in the PMRP biobank. The observation that lipid levels trend in the direction anticipated clinically (that is, HDL decreases while TGs increase) suggests that these algorithms can be applied to existing electronic data across large health care networks to characterize outcome on an unprecedented scale. (Figure  3 ). The accuracy of these algorithms has been published. 106 By linking high-throughput genotyping technologies to electronic health care records within the context of these biobanks, improved risk prediction models will eventually allow investigators to distinguish the genetic architecture underlying specific cardiac risk factors (for example, baseline HDL cholesterol level) from the genetic architecture underlying response to treatment (for example, change in HDL cholesterol level induced by a pharmacologic intervention). However, this effort will require cohorts of extremely large sample size. 108, 109 BioVU, located at Vanderbilt University, is currently the largest population-based biobank in the United States. At present, enrollment is approaching 80 000 unique subjects. It is anticipated that BioVU will contain DNA and securely encrypted clinical data from more than 100 000 study subjects by the end of the current academic year. To illustrate the potential of this resource to facilitate large scale studies of outcome related to the management of low HDL cholesterol, the number of participants with various metabolic traits related to body composition has been summarized below (Table 1) .
These phenotypes are highly intercorrelated. For example, in obese study subjects, diabetes mellitus often represents the extreme end of a disease process known to occur along a clinical continuum. Pre-diabetic states include IFG and impaired glucose tolerance. The former (IFG) is defined by fasting glucose levels above 100 mg per 100 ml (reference 110). Clinical derangements in lipid homeostasis often become evident in subjects with IFG long before they develop diabetes mellitus. As shown above, there are many different permutations of these phenotypic subsets. Because all permutations of these cardiometabolic risk determinants do not carry the same risk, 2, 111 clinical intervention must be guided by a more thorough High-density lipoprotein cholesterol
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understanding of their interactions within the community. It remains uncertain whether genetic markers will provide added value. Although investigators within the Pharmacogenetics and Pharmacogenomics Research Network have begun characterizing the genetic determinants contributing to change in lipid levels within the context of treatment trials, these markers will need to be tested for generalizability in population-based cohorts that can be stratified according to the cardiometabolic risk determinants shown above. Table 2 represents a compilation of the genetic predictors of HDL cholesterol from three treatment trials, before and after exposure to atorvastatin, simvastatin or pravastatin (adapted from Barber et al. 49 ) . Although baseline HDL level was associated with single nucleotide polymorphisms in several well-characterized biological candidate genes (CETP, LIPC, LPL), no single nucleotide polymorphisms were associated with treatment-induced change in HDL (that is, all frequentist P-values for the difference trait were 40.05, and posterior probabilities were low for H D ). Conversely, our analyses did identify an association between another wellcharacterized candidate gene (GCKR) and statin-induced changes in fasting triglyceride levels (data not shown). 49 Due to the heterogeneity of low HDL dyslipidemia as a clinical phenotype, the small contribution of individual genetic risk determinants, and the complexity of the genetic architecture underlying response to pharmacological intervention, the construction of accurate risk prediction models will require the coordinated sharing of data across institutions. Academic medical centers are utilizing electronic health records to merge practice-based data sets on an unprecedented scale. 112 As these biobanks become linked, the scientific community will draw nearer to personalized medicine within the context of dyslipidemia.
Summary
Clinical data available in population-based biobanks should facilitate the construction of accurate risk prediction models by integrating various combinations of cardiometabolic risk determinants with a variety of cardiovascular outcomes.
As the scientific community moves rapidly toward largescale application of genetic epidemiology and pharmacogenetics, the world's population-based biobanks represent a unique resource for assessing clinical variables in directing the care of complex phenotypes like dyslipidemia (www.gwas.net).
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